Changes to lamotrigine

Applications to fund Arrow-Lamotrigine and Lamictal

Total number of patients: 2,526

Applications under assessment: 21

Approved: 2,418

Declined: 78

Withdrawn: 9

The number of declined applications has increased because dispensing data indicated that these applications were for people who:

  • were not previously on another brand of lamotrigine and for who Logem is an appropriate treatment option or
  • had not been prescribed lamotrigine for mental health or epilepsy indications. 

> Read the criteria for funding alternative brands of lamotrigine

As at: 14 July 2020

Last updated: 16 July 2020

Discontinuation of Arrow-Lamotrigine 5 mg 

Information about 2019 brand change updated